Identifying adherence barriers to oral endocrine therapy among breast cancer survivorsRutugandha Paranjpe, Susan Abughosh, Grace C. John et al.|Breast Cancer Research and Treatment|2018Cited by 99
Neratinib in HER2-Positive Breast Cancer PatientsRutugandha Paranjpe, Meghana V. Trivedi, Dima Basatneh et al.|Annals of Pharmacotherapy|2019Cited by 30
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic InstitutionGrace Hwang, Meghana V. Trivedi, Susan Abughosh et al.|Clinical Breast Cancer|2020Cited by 17
Identifying Adherence Barriers To Oral Endocrine Therapy (OET) Among Breast Cancer PatientsRutugandha Paranjpe, Susan Abughosh, Meghana V. Trivedi|Value in Health|2018Cited by 2
Abstract A138: Evaluating medication adherence of oral endocrine therapy among breast cancer survivors in a large academic medical centerRutugandha Paranjpe, Meghana V. Trivedi, Grace Hwang et al.|Cancer Epidemiology Biomarkers & Prevention|2020Cited by 1